Pharmacodynamics of PEG-IFN-alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients

  • E.S.A. D
  • H. D
  • S.J. C
  • et al.
N/ACitations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We examined the association between IL28B single-nucleotide polymorphism rs12979860, hepatitis C virus (HCV) kinetic, and pegylated interferon alpha-2a pharmacodynamic parameters in HIV/HCV-coinfected patients from South America. Twenty-six subjects received pegylated interferon alpha-2a + ribavirin. Serum HCV-RNA and interferon concentrations were measured frequently during the first 12 weeks of therapy and analyzed using mathematical models. African Americans and whites had a similar distribution of IL28B genotypes (P = 0.5). The IL28B CC genotype was overrepresented (P = 0.015) in patients infected with HCV genotype-3 compared with genotype-1. In both genotype-1 and genotype-3, the first-phase viral decline and the average pegylated interferon-alpha-2a effectiveness during the first week of therapy were larger (trend P <= 0.12) in genotype-CC compared with genotypes-TC/TT. In genotype-1 patients, the second slower phase of viral decline (days 2-29) and infected cells loss rate, delta, were larger (P = 0.02 and 0.11, respectively) in genotype-CC than in genotypes-TC/TT. These associations were not observed in genotype-3 patients. © 2011 Lippincott Williams & Wilkins.

Cite

CITATION STYLE

APA

E.S.A., D. A., H., D., S.J., C., T.J., L., A.U., N., & C.E., M. (2011). Pharmacodynamics of PEG-IFN-alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. Journal of Acquired Immune Deficiency Syndromes, 56(2), 95–99. https://doi.org/http://dx.doi.org/10.1097/QAI.0b013e3182020596

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free